At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Omeprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate the Impact of Omeprazole, A Proton Pump Inhibitor, on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Omeprazole and Sotorasib for Healthy Volunteers. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The primary objective of the study is to evaluate the effects of omeprazole (a proton-pump inhibitor) and an acidic beverage (Coca-Cola) on sotorasib pharmacokinetics (PK) when administered orally in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedAug 2022
Primary CompletionSep 2022
TodayJul 2026
First PostedAug 11, 2022
Enrollment StartJul 14, 2022
Primary CompletionSep 8, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.9 years ago
Interventions
Omeprazoledrug
Omeprazole will be administered as an oral capsule.
Sotorasibdrug
Sotorasib will be administered as an oral tablet.